ArticleTherapeutic advances in chronic disease2010
Bisphosphonates for the treatment of osteoporosis: insights for clinicians.
Article in Therapeutic advances in chronic disease, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it, 105 citations in OpenAlex.
- Efficacy and safety of Romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis.Clinical rheumatology · 2020Pooled it
- Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review.BMJ open · 2019Pooled it
- Does Zoledronic Acid Improve Appendicular Lean Mass in Older Women with Osteoporosis? A Sub-Analysis of a Randomized Clinical Trial.The Journal of frailty & aging · 2022Trial
- Effectiveness of monthly intravenous ibandronate on the low responders to oral bisphosphonate: the MOVEMENT study.Journal of bone and mineral metabolism · 2019Trial
- Insights into the bisphosphonate holiday: a preliminary FTIRI study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2018Trial
- Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study.JAMA internal medicine · 2014Trial
- Synthesis of a Series of Heterocyclic N-Substituted Derivatives of Alendronic Acid and Their Preliminary Biological Evaluation.Chemistry & biodiversity · 2026Article
- Targeting the osteoporotic bone microenvironment: Mechanistic insight and therapeutic biomaterials for accelerating bone regeneration.Bioactive materials · 2026Review
- Article
- Therapeutic functions of tanshinone IIA in a zebrafish model of glucocorticoid-induced osteoporosis.Frontiers in pharmacology · 2026Article
- Musculoskeletal changes and treatments in paediatric spinal cord disorders: A scoping review.Journal of pediatric rehabilitation medicine · 2025Article
- Perceptions and Attitudes Toward Oral Semaglutide Among Japanese Physicians and Individuals with Type 2 Diabetes: A Web-Based Survey.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Real-World Evaluation of 12-Month Romosozumab Treatment in Korean Women with Severe Osteoporosis: Potential Synergy with Hormone Therapy.Journal of clinical medicine · 2025Article
- Targeted Dual Microdroplets for Modulating Osteoclast Differentiation and Function: A Novel Therapeutic Approach to Combat Osteoporosis.ACS applied materials & interfaces · 2025Article
- Use of bisphosphonates in chronic kidney disease is associated with cardiovascular death.Clinical nephrology · 2025Observational
- Methyl-Beta-Cyclodextrin Restores Aberrant Bone Morphogenetic Protein 2-Signaling in Bone Marrow Stromal Cells Obtained from Aged C57BL/6 Mice.Journal of developmental biology · 2024Article
- Osteoporosis management-current and future perspectives - A systemic review.Journal of orthopaedics · 2024Review
- Insights into the Mechanism of Osteoporosis and the Available Treatment Options.Current pharmaceutical biotechnology · 2024Review
- Bisphosphonates' use and risk of aseptic loosening following total hip arthroplasty: a systematic review.EFORT open reviews · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is a common skeletal disease characterized by a reduction in bone strength and increased risk of fractures. Osteoporotic fractures are associated with substantial morbidity, mortality, and high healthcare costs. Treatments for osteoporosis have been shown to increase bone strength and reduce fracture risk. The drugs most commonly used to treat osteoporosis are bisphosphonates: stable analogs of naturally occurring inorganic pyrophosphate. The bisphosphonates share a common chemical structure with side chain variations that convey differences in their pharmacological properties, such as affinity for bone mineral and inhibitory effect on osteoclastic bone resorption. The clinical profiles of bisphosphonates, such as time of onset and offset of effect, may differ according to these pharmacological properties. Bisphosphonates can be administered orally or intravenously with a wide range of doses and dosing intervals. Randomized placebo-controlled clinical trials have shown that bisphosphonates reduce fracture risk in postmenopausal women with osteoporosis and have a generally excellent safety record. Clinical challenges in using bisphosphonates to treat osteoporosis include appropriate selection of patients for initiating therapy, choosing which bisphosphonate to use, monitoring therapy to assure that medication is taken correctly and the desired effect is achieved, determining when drug discontinuation should be considered, and managing side effects, possible side effects, and fear of side effects. Strategies for treating patients with bisphosphonates should consider each of these issues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.